Next Up For AstraZeneca: Building Out In Renal Disease
US President Ruud Dobber talked to Scrip about expanding in renal disease, balancing the fast-growing oncology portfolio against other priority disease areas, and the company's anticipated return to growth. The big challenge going into 2019, he said, is external factors. "I'm not able to change the view of the President," he said.
You may also be interested in...
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.
Positive top-line Phase III data from five studies, including the finding of superior efficacy to epotin-alfa, puts roxadustat in the driving seat as a new class of anemia agents heads toward the marketplace, but cardiovascular safety needs confirming.